We, Kyowa Hakko Europe GmbH (hereinafter referred as to KHE) are pleased to announce that as of April 1st, 2009 Daiichi Fine Chemical Europe GmbH (hereinafter referred as to DFE) will be merged into KHE, and KHE will become the successor to all of DFE's business. At the same time the Sales and Marke...
KYOWA HAKKO BIO and Daiichi Fine Chemical integrate its European entities
17 February 2009
Dear valued customers:
We have the pleasure to announce to you that KYOWA HAKKO BIO CO., LTD., Tokyo, Japan (KHB), KYOWA HAKKO KIRIN’s Biochemical affiliate, reorganizes its European whole owned entities effective as of April 1st, 2009 with the merger of KYOWA HAKKO EUROPE GmbH (KHE...
KYOWA HAKKO BIO aims to maximize Daiichi Fine Chemical’s activities
01 October 2008
Dear valued customers:
We have a pleasure to announce to you, that the new company, KYOWA HAKKO BIO CO., LTD., Tokyo, Japan (KHB) is established effective as of October 1st, 2008. As a strategic spinning off from Kyowa Hakko Kogyo Co., Ltd., with the view of further strengthening and expansion...
Kyowa Hakko Fiscal 2007 Operating Income up 28.3%: Sales and Operating Income Exceed Plan Targets
28 April 2008
Tokyo, April 28, 2008 --- Kyowa Hakko Kogyo Co. Ltd. (Kyowa Hakko) today announced its consolidated financial results for the year ended March 31, 2008 (Fiscal 2007). Consolidated net sales were Yen 392.1 billion, up 10.7% and consolidated operating income was Yen 39.3 billion, an increase of...
Kyowa Hakko Kirin Group: Medium-term Business Plan FY2008-2010
28 April 2008
Tokyo, April 28, 2008 -- Kyowa Hakko Kogyo Co., Ltd. (Kyowa Hakko; TSE 4151) today announced the Kyowa Hakko Kirin Group Medium-term Business Plan for the period from fiscal 2008-2010.
The core of the plan is based on the integration of Kyowa Hakko and Kirin Pharma Company, Limited (Kirin P...
ARANA AND KYOWA HAKKO TO CO-DEVELOP ANTI-CANCER DRUG
24 April 2008
Arana Therapeutics Limited, and Kyowa Hakko Kogyo Co., Ltd. (Kyowa Hakko), a major Japanese biotechnology company, today announced they have entered into an agreement to co-develop a new anti-cancer drug for colorectal cancer (ART104).
Pie de imprenta